Will the Accreditation Bodies selected by SAMHSA/CSAT have direction or guidance in how and what to review when surveying an Opioid Agonist Treatment Program?
Yes. Beginning in 1996, CSATs Division of Pharmacologic Therapies (DPT), co>nvened a special field-based Guideline Development Panel of Methadone and LAAM treatment experts and consumer advocates to provide content input to SAMHSA/CSAT as it began the process of developing guidelines for the accreditation organizations. J. Thomas Payte, M.D., Medical Director of Drug Dependence Associates and Co-Chair of the American Society of Addiction Medicines Committee on Methadone Treatment, chaired the Panel. The Panel met numerous times reviewing and refining the document prior to its release in April, 1999 as the “Guidelines for the Accreditation of Opioid Treatment Programs.” All SAMHSA/CSAT approved accrediting bodies are required to base their standards on the SAMHSA regulations. Additionally, the CSAT Guidelines for the Accreditation of Opioid Treatment Programs have been provided to the accreditation bodies to help implement the SAMHSA regulations and guide their development and adaptatio
Related Questions
- Will the Accreditation Bodies selected by SAMHSA/CSAT have direction or guidance in how and what to review when surveying an Opioid Agonist Treatment Program?
- Once a continued stay review is certified, will the same case ever be selected for retrospective post-payment review?
- How many audit working papers are normally selected for QA review purpose?
